<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013685</url>
  </required_header>
  <id_info>
    <org_study_id>TRGFT-201</org_study_id>
    <nct_id>NCT04013685</nct_id>
  </id_info>
  <brief_title>A Study of Engineered Donor Grafts (TregGraft/Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies</brief_title>
  <official_title>A Multicenter Phase Ib Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With TregGraft (Orca-T), a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orca Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orca Biosystems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft&#xD;
      (&quot;TregGraft&quot;/&quot;Orca-T&quot;, a T-cell-Depleted Graft With Additional Infusion of Conventional T&#xD;
      Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic&#xD;
      hematopoietic cell transplant transplantation for hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TregGraft (Orca-T), with single agent GVHD prophylaxis</measure>
    <time_frame>365 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival (OS)</measure>
    <time_frame>365 days</time_frame>
    <description>1-year overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year graft-versus-host-disease-free and relapse-free survival (GRFS)</measure>
    <time_frame>365 days</time_frame>
    <description>1 year graft-versus-host-disease-free and relapse-free survival (GRFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of acute and chronic graft vs host disease (GvHD)</measure>
    <time_frame>365 days</time_frame>
    <description>incidence and severity of acute and chronic graft vs host disease (GvHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of serious infections</measure>
    <time_frame>365 days</time_frame>
    <description>incidence of serious infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and timing of engraftment</measure>
    <time_frame>28 days</time_frame>
    <description>incidence and timing of engraftment of platelets and neutrophils</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Leukemia</condition>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)</condition>
  <arm_group>
    <arm_group_label>Subjects with Acute Leukemia or Myelodysplasic Syndrome, Myelofibrosis, or BPDCN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a non-randomized, single-arm study. Patients will be grouped based on their underlying disease:&#xD;
Group 1 will enroll subjects planning to undergo myeloablative allogeneic hematopoietic cell transplantation (MA-alloHCT) for the treatment of either acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi), and with no known minimal residual disease positivity.&#xD;
Group 2 will enroll subjects Subjects planning to undergo MA-alloHCT for acute myeloid, lymphoid or mixed phenotype leukemia that is either:&#xD;
not in morphologic CR with bone marrow infiltration by leukemic blasts of &lt;= 10%, or&#xD;
in morphologic CR with evidence of minimal residual positivity by either multiparameter flow cytometric analysis or by a nucleic acid-based technique.&#xD;
Group 3 will enroll subjects planning to MA-alloHCT for high or very high risk myelodysplasic syndrome (MDS) myelodysplastic syndromes, myelofibrosis or BPDCN</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TregGraft (Orca-T)</intervention_name>
    <description>engineered donor allograft</description>
    <arm_group_label>Subjects with Acute Leukemia or Myelodysplasic Syndrome, Myelofibrosis, or BPDCN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Recipients must meet all of the following criteria:&#xD;
&#xD;
          1. Patients must diagnosed with one of the following histopathologically confirmed&#xD;
             diseases, for which a myeloablative hematopoietic stem cell transplant (HCT) is&#xD;
             planned:&#xD;
&#xD;
               -  acute myeloid, lymphoid or mixed phenotype leukemia&#xD;
&#xD;
               -  high or very high risk myelodysplastic syndromes&#xD;
&#xD;
               -  Myelofibrosis&#xD;
&#xD;
               -  Blastic Plasmacytoid Dendritic Cell Neoplasm&#xD;
&#xD;
          2. Patients with active acute leukemia (i.e. not in morphologic complete response) must&#xD;
             have bone marrow infiltration by leukemic blasts of &lt;= 10%,&#xD;
&#xD;
          3. Patients must be matched to a related or unrelated donor&#xD;
&#xD;
          4. Estimated glomerular filtration rate (eGFR) &gt; 50 mL/minute&#xD;
&#xD;
          5. Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by&#xD;
             echocardiogram or radionuclide scan (MUGA)&#xD;
&#xD;
          6. Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥&#xD;
             50%&#xD;
&#xD;
          7. Total bilirubin &lt; 2 times upper limit of normal (ULN) (patients with Gilbert's&#xD;
             syndrome may be included where hemolysis has been excluded) and ALT/AST &lt; 3 times ULN&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Recipients meeting any of the following exclusion criteria will not be eligible:&#xD;
&#xD;
          1. History of prior allogeneic HCT&#xD;
&#xD;
          2. Currently receiving corticosteroids or other immunosuppressive therapy. Topical&#xD;
             corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day&#xD;
             are allowed.&#xD;
&#xD;
          3. Pre-planned donor lymphocyte infusion (DLI)&#xD;
&#xD;
          4. Planned pharmaceutical in vivo or ex vivo T cell depletion&#xD;
&#xD;
          5. Positive for anti-donor HLA antibodies against an allele in the selected donor&#xD;
&#xD;
          6. Karnofsky performance score &lt; 70%&#xD;
&#xD;
          7. Hematopoietic cell transplantation-specific Comorbidity Index (HCT-CI) &gt; 4&#xD;
&#xD;
          8. Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial&#xD;
             therapy and with progression or no clinical improvement) at time of enrollment&#xD;
&#xD;
          9. Seropositive for HIV-1 or -2 antibody, HTLV-1 or -2 antibody, Hepatitis B sAg, or&#xD;
             Hepatitis C antibody&#xD;
&#xD;
         10. Any uncontrolled autoimmune disease requiring active immunosuppressive treatment&#xD;
&#xD;
         11. Concurrent malignancies or active disease within 1 year, except non-melanoma skin&#xD;
             cancers that have been curatively resected&#xD;
&#xD;
         12. Women who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James S McClellan, MD PhD</last_name>
    <phone>530-414-9743</phone>
    <email>info@orcabiosystems.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandeep Salhotra</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caspian Oliai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rasmus Hoeg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Everett Meyer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute - Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edmund Waller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satyajit Kosuri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph McGuirk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Van Besien</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University - Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arpita Gandhi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Pantin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhagirathbhai Dholaria</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rohtesh Mehta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Behyar Zoghi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagar Patel</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>Myelodysplastic syndromes</keyword>
  <keyword>matched related donor</keyword>
  <keyword>matched unrelated donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

